This finding was further supported by various studies: (1) IL-6-deficient mice are protected from Ang II-induced muscle wasting [24]; (2) Losartan treatment prevented the tumor-induced loss of muscle mass and attenuated the myocardial expression of IL-6 [15]; (3) In heart failure patients, elevated levels of IL-6 were associated with a reduced LV ejection fraction and poor clinical outcomes [46]. This evidence concerns the gene IL6 and heart failure.